ARTICLE
ecn.2011.0295
Auteur(s) : Atefeh Golpaie1,2, Narges Tajik1,2, Farzad Masoudkabir3, Zohreh Karbaschian1, Mohammad Talebpour2,4, Mostafa Hoseini5, Hosseinzadeh-Attar MJ1,2 hosseinzadeh.md.phd@gmail.com
1 Department of Nutrition and Biochemistry, School of
Public Health and Institute of Public Health Research, Tehran
University of Medical Sciences, Tehran, Iran
2 Endocrine and Metabolism Research Center (EMRC),
Obesity and Food group set, Tehran University of Medical Sciences,
Tehran, Iran
3 Students'Scientific Research Center (SSRC), Tehran
University of Medical Sciences, Tehran, Iran
4 Department of Surgery, Laparoscopic Surgical Ward
,Sina hospital, Tehran University of Medical Sciences, Tehran,
Iran
5 Epidemiology and Biostatistics Department, School
of Public Health, Tehran University of Medical Sciences, Tehran,
Iran
Correspondence: Mohammad Javad Hosseinzadeh-Attar,
Department of Nutrition and Biochemistry, School of Public Health
and Institute of Public Health Research, Tehran University of
Medical Sciences, Poursina Ave., Qods St., Tehran, Iran, Zip code:
141556446.
Obesity is recognized as a continuously growing, global public
health problem. It is associated with increased risk of a variety
of acute and chronic disorders, such as type II diabetes mellitus,
dyslipidemia, and cardiovascular disease (CVD) [1,2]. In addition
to storing excess energy, adipose tissue secretes several bioactive
peptides, termed “adipokines”, that play important roles in
metabolic homoeostasis through endocrine, paracrine, or autocrine
pathways [3-8]. Thus, to explain the mechanisms for the
epidemiological relationship between obesity and increased
metabolic risk, the main focus has been on adipokine secretion and
action.
Visceral adipose tissue-derived serine protease inhibitor
(vaspin) is a newly-discovered adipokine with insulin-sensitizing
properties, and was originally isolated from the visceral adipose
tissue of Otsuka Long-Evans Tokushima Fatty (OLETF) rats [9], a
rodent model for insulin resistance and abdominal obesity, and was
then found to be expressed in white adipose tissue of obese humans
[10]. Although controversial, there is evidence from both animal
and clinical studies that vaspin mRNA expression in adipose tissue,
as well as its circulating levels, correlate with insulin
resistance and obesity [9-20]. Hence, it has been proposed that
elevated serum vaspin levels in obese subjects might be a
compensatory response to obesity-induced insulin resistance [21].
Until now, molecular target(s) of vaspin and its mode of action
have remained unelucidated [22]. However, based upon previous data
on vaspin action, it might be postulated that vaspin acts through
inhibition of a protease that degrades a hormone or molecule with a
direct or indirect glucose-lowering effect [22].
Chang et al. [11] recently reported decreased levels of
serum vaspin after a modest weight loss in obese subjects that was
accompanied by improvements in parameters of insulin sensitivity.
Similarly, Handisurya et al. [14] recently reported a
reduction in circulating levels of vaspin following laparoscopic
Roux-enY gastric bypass (RYGB) surgery in morbidly obese subjects.
However, the effect of restrictive bariatric surgery on circulating
vaspin levels had not yet been investigated. Moreover, in an animal
study, Wang et al. [23] recently reported that dietary
intake is related to serum and adipose tissue concentrations of
vaspin. The relationship between dietary intake and vaspin
concentrations in humans, and its potential for explaining the
effect of bariatric surgery on serum vaspin concentrations have not
been clearly documented.
The aims of this study were two-fold: firstly, to investigate
the possible short-term effects of restrictive bariatric surgery on
serum levels of vaspin and other metabolic variables relevant to
insulin sensitivity, and secondly, to evaluate the possible
relationship between dietary intake and serum vaspin concentrations
in obese subjects.
METHODS AND SUBJECTS
Study population
Between September 2009 and October 2010, severely obese patients
older than 15 years, with a body mass index (BMI) of more than
40 kg/m2 consecutively submitted to restrictive
bariatric surgery, were enrolled in the study. Exclusion criteria
were the following: diabetes mellitus; hypo- or hyperthyroidism;
Cushing syndrome, hypertension and/or use of anti-hypertensive
drugs, a history of convulsion and/or use of antiepileptic drugs;
liver disease; kidney disease; ischemic heart disease; cancer;
rheumatoid arthritis; symptoms of acute or chronic infection;
current smoking and alcohol intake; pregnancy or lactating; use of
hormonal contraception, lipid-lowering drugs (statins, fibrates)
and/or antiglycemic medications (metformin, thiazolidinediones,
insulin). The study protocol was approved by the ethics committee
of Tehran University of Medical Sciences and written, informed
consent was obtained from all subjects.
Study protocol
Patients underwent a clinical assessment including medical
history, physical examination and co-morbidity evaluation by a
multidisciplinary consultation team. In addition, for all patients,
assessment of dietary intake, physical activity, anthropometric
measurements and blood sampling for biochemical assays were
performed prior to, and six weeks after surgery.
Bariatric surgery
All patients met the criteria detailed by the National
Institutes of Health for patient selection to undergo bariatric
surgery for morbid obesity [24]. Patients underwent restrictive
bariatric surgery using one of two techniques: laparoscopic
adjustable gastric banding (LAGB) and laparoscopic total gastric
vertical plication (LTGVP). Patient preference determined the type
of surgery performed. All patients were operated on by a single
team.
LAGB surgeries were performed according to the
pars-flaccida technique described elsewhere [25]. This
technique involves the placement of an adjustable, silicone,
gastric band containing an inflatable inner balloon that can be
adjusted by adding or removing saline via a small, subcutaneous
access port.
LTGVP was performed according to the technique described by
Talebpour and Amoli [26]; briefly, patients were placed in the
supine position with a 30-degree reverse Trendelenburg position.
After the release of the greater curvature, continuous suturing
from the fundus of the stomach to the antrum, making one or two
layers of plication from the anterior wall of the stomach to its
posterior wall, was performed.
Measurements of anthropometric indices and blood pressure
Qualified, trained staff measured anthropometric indices and
blood pressure prior to, and six weeks after surgery. Body weight
was measured to the nearest 0.1 kg using a calibrated manual
weighing scale (Seca 709, Les Mureaux, France). Height was measured
to the nearest 0.5 cm on a standardized wallmounted height
board. Waist circumference (WC) was measured at the minimum
circumference between the iliac crest and the rib cage at minimal
respiration. Hip circumference was measured at the maximum
protuberance of the buttocks, and the waist-to-hip ratio (WHR) was
calculated. BMI was defined as weight in kilograms divided by
height in meters squared (kg/m2). For measuring the
blood pressure, the participants remained at rest for at least
15 minutes, then the same staff measured blood pressure using
the right arm and in a sitting position.
Dietary intake and physical activity assessment
All enrolled subjects received instructions to record their
daily dietary intake for three days (two non-consecutive weekdays
and a weekend). Records were reviewed and analyzed by a dietitian.
The nutrient composition program, Food Processor, version 2.0
(ESHA Research, Salem, OR, USA) was used to estimate macro- and
micronutrient intakes. Subjects self-reported physical activity
using the International Physical Activity Questionnaire-Short form
for the previous seven days [27].
Laboratory assays
Between 8:00 and 10:00 a.m., peripheral venous blood
specimens were collected from an antecubital vein after
10-12 hours overnight fasting. Blood samples were centrifuged
at 3,000 g for 10 min and the resultant plasma samples
were stored at -80 ̊C until analysis.
Serum vaspin concentrations were determined using an
enzyme-linked immunosorbent method (Human vaspin ELISA kit,
AdipoGen Pharmaceuticals, Seoul, South Korea) with a detection
limit of 12 pg/mL and an intra-assay and inter-assay
variability of 1.3-3.8 and 3.3-9.1%, according to the manufacturer.
Fasting plasma glucose was measured using the glucose-oxidation
method (Pars Azmoon, Tehran, Iran), and total cholesterol (TC),
triglyceride (TG), and low density lipoprotein-cholesterol (LDL-C)
were determined by enzyme colorimetric assay (Pars Azmoon, Tehran,
Iran) using an Eppendorf autoanalyzer (Eppendorf Corp., Hamburg,
Germany). High density lipoprotein-cholesterol (HDL-C) was measured
using a precipitation-based method. Serum insulin level was assayed
using an immunoradiometric method (Biosource Europe SA, Belgium).
The insulin sensitivity was determined using the Homeostasis Model
Assessment (HOMA) index with formula: HOMA-IR=fasting
insulin (μU/mL) × fasting glucose (mmol/l)/22·5 [28].
Statistical analysis
The Kolmogorov-Smirnov test was applied to examine normal
distribution. Data are presented as mean ± SD for numeric
variables, and absolute frequencies with percentages in parentheses
for categorical variables. Numeric variables were compared using
the paired sample t-test or the equivalent non-parametric
procedure (Wilcoxon test) whenever the presumption of normality was
not met. To determine the relationship between the various
metabolic and anthropometric parameters, and plasma levels of
vaspin at baseline as well as after surgery, Pearson's correlation
was used. Linear regression analysis was performed to identify
independent predictors of serum vaspin concentrations. For the
statistical analysis, the statistical package SPSS version 13.0 for
Windows (SPSS Inc, Chicago, Illinois, USA) was used. All p
values were 2-tailed with a statistical significance defined by
p≤0.05).
Results
Out of a total of 30 study subjects compatible with our
selection criteria (mean age of 32.5 ± 9.2 years), 21
(70.0%) were women. Fifteen patients underwent LAGB and the
remaining subjects underwent LTGVP surgery. The clinical and
nutritional characteristics of the study participants at baseline
and six weeks after surgery are presented in table 1.
Table 1 Clinical and nutritional characteristics of the
study population at baseline and six weeks after restrictive
bariatric surgery*
|
| Before surgery |
6 weeks after surgery |
P value |
| Clinical characteristics |
|
| |
| Age (year) |
32.5 ± 9.2 |
| |
| Weight (kg) |
126.2 ± 19.9 |
109.7 ± 18.1 |
<0.0001 |
| Body mass index (kg/m2) |
44.1 ± 4.9 |
38.4 ± 4.9 |
<0.0001 |
| Waist circumference (cm) |
122.3 ± 15.1 |
110.1 ± 13.4 |
<0.0001 |
| Waist-to-hip ratio |
0.90 ± 0.10 |
0.87 ± 0.10 |
0.017 |
| Systolic blood pressure (mmHg) |
117.0 ± 13.7 |
109.3 ± 25.8 |
0.262 |
| Diastolic blood pressure (mmHg) |
75.2 ± 10.7 |
71.4 ± 17.0 |
0.307 |
| Dietary intake |
|
| |
| Daily calorie intake (kcal) |
2258.0 ± 803.4 |
621.7 ± 301.0 |
<0.0001 |
| Protein (g) |
76.6 ± 24.6 |
28.8 ± 14.0 |
<0.0001 |
| Lipid (g) |
90.9 ± 38.3 |
24.9 ± 17.3 |
<0.0001 |
| Carbohydrate (g) |
289.0 ± 126.0 |
73.7 ± 41.2 |
<0.0001 |
| Fiber (g) |
16.7 ± 8.2 |
5.9 ± 4.3 |
<0.0001 |
| IPAQ score |
1.07 ± 0.25 |
1.04 ± 0.5 |
0.001 |
* All plus-minus values are mean±SD. IPAQ,
International Physical Activity Questionnaire.
Patients lost an average of 16.4 ± 5.8 kg (13.1%)
during the six weeks following surgery. Restrictive bariatric
surgery resulted in significant reductions in BMI, WC and WHR
during the 6-week follow-up period. Daily intake of total calories
(2,258.0 ± 803.4 vs 621.7 ± 301.0,
p<0.0001) and all macronutrients were also decreased
after bariatric surgery. We observed decreased levels of physical
activity in study participants six weeks after surgery (table 1).
Table 2 demonstrates the blood
biochemistry profile of the study participants before and after the
bariatric surgery. No significant change was observed in lipid
profiles, apart from TG, which significantly decreased following
bariatric surgery (180.4 ± 118.9 vs
135.7 ± 51.8, p=0.03). A borderline significant
reduction in plasma levels of LDL-C was also observed after surgery
(111.9 ± 30.2 vs 105.6 ± 23.1,
p=0.095). Following bariatric surgery, fasting plasma
insulin and HOMA-IR did not decrease significantly.
Table 2 Serum biochemistry profile of study subjects
before and six weeks after restrictive bariatric surgery*
|
| Before surgery |
6 weeks after surgery |
P value |
| LDL-C (mg/dL) |
111.9 ± 30.2 |
105.6± 23.1 |
0.095 |
| HDL-C (mg/dL) |
39.0 ± 9.2 |
37.3 ± 6.7 |
0.144 |
| Total cholesterol (mg/dL) |
188.1 ± 41.8 |
184.2 ± 32.9 |
0.528 |
| Triglycerides (mg/dL) |
180.4 ± 118.9 |
135.7 ± 51.8 |
0.030 |
| Fasting glucose (mg/dL) |
96.2 ± 9.6 |
93.1 ± 6.7 |
0.148 |
| Fasting insulin (mu/L) |
14.7 ± 9.3 |
11.9 ± 4.3 |
0.199 |
| HOMA-IR |
3.3 ± 2.2 |
2.8 ± 1.1 |
0.163 |
| Vaspin (ng/mL) |
0.36 ± 0.20 |
0.26 ± 0.17 |
0.048 |
* All plus-minus values are mean±SD. LDL-C,
low-density lipoprotein cholesterol; HDL-C, high-density
lipoprotein cholesterol; HOMA-IR, homeostasis model assessment of
insulin resistance.
As presented in table 2, six weeks
after restrictive bariatric surgery a significant decrease was seen
in circulating levels of vaspin (Δ=-27.8%, p=0.045).
At baseline, vaspin concentrations did not significantly
correlate with parameters of insulin resistance, anthropometric
indices, lipid profile, dietary intake or physical activity.
Following bariatric surgery, although circulating levels of vaspin
did not show any significant correlation with parameters of insulin
resistance, anthropometric indices, lipid profile and physical
activity, it correlated significantly with total daily calorie
intake (r=0.397, p=0.030) as well as daily intake of
fat (r=0.371, p=0.043) and protein (r=0.477,
p=0.008). We also observed a significant correlation between
percentage change in vaspin serum levels and percent change in
total daily calorie intake (r=0.389, p=0.046), as
well as percentage change in daily intakes of fat (r=0.505,
p=0.010) and protein (r=0.384, p=0.050). In a
multivariate linear regression model, the association between
percentage change in circulating vaspin levels and percentage
change in total daily calorie intake (β=1.71, p=0.055) as
well as percent changes in daily intakes of fat (β=2.47,
p=0.004) and protein (β=1.23, p=0.053) remained
significant even after adjustment for sex and percent changes in WC
and HOMA-IR.
While HOMA-IR did not correlate with anthropometric indices,
lipid profile, dietary intakes or physical activity at baseline, it
showed significant correlations with male gender (r=0.378,
p=0.039), WC (r=0.497, p=0.005), WHR
(r=0.477, p=0.008), plasma levels of TG
(r=0.407, p=0.026), and daily carbohydrate intake
(r=0.383, p=0.037) following bariatric surgery.
Discussion
The present study demonstrates, for the first time, that
restrictive bariatric surgery is accompanied by a significant
decrease in serum vaspin concentrations.
Our study agrees with previous studies that investigated the
effect of weight reduction/lifestyle modification programs on
circulating vaspin levels in obese subjects
[12, 14, 16, 17]. Handisurya et al. [14]
reported decreased levels of vaspin in the serum of morbidly obese
subjects 12 months after RYGB surgery. Chang et al. [11]
observed that a 12-week weight reduction program through
restriction of daily energy intake by 500 kcal, regular
exercise and treatment with the anti-obesity drug
Orlistat®, significantly reduced serum vaspin in obese
subjects. Lee et al. [16] have also shown reduced levels of
vaspin following seven days of intensive lifestyle modification in
overweight and obese children. Oberbach et al. [17] observed
that vaspin levels decreased significantly after both short-term
and long-term physical activity.
Currently, data on the association between circulating vaspin
and obesity are conflicting. While Kloting et al. [10], Cho
et al. [13], Korner et al. [15], and Youn et
al. [20] reported a positive correlation between obesity and
serum levels of vaspin and/or its mRNA expression in adipose
tissue, the correlation was more subtle or indeed absent in more
recent studies [14, 19, 29, 30]. Although Chang
et al. [12] observed a positive correlation between serum
vaspin concentrations and the visceral adipose tissue area in
insulin-resistant subjects, they observed no correlation between
the visceral adipose tissue area and BMI or WC. In another study by
the same group [11], a significant correlation between changes in
vaspin concentrations and BMI and WC, in insulin-resistant patients
who had undergone a weight reduction program was observed. In our
study, we found no correlation between serum vaspin concentrations
and anthropometric indices. Moreover, the changes in circulating
vaspin levels did not correlate with the changes in BMI or WC
following bariatric surgery. In concordance with our findings,
Handisurya et al. [14] reported no significant correlation
between serum vaspin concentrations and BMI after RYGB surgery. The
exact reason for such a discrepancy remains to be elucidated.
However, it might be explained by the findings of Aust et
al. [29]. They observed a U-shaped relationship between body
mass and plasma vaspin concentrations in elderly, overweight
subjects with carotid stenosis. Von Loeffelholz et al. [19]
similarly observed that circulating vaspin levels increased with
BMI only in males, while in the group of females, they
paradoxically observed the highest serum levels in normal weight
subjects and accordingly, no significant correlation between vaspin
and BMI was detectable in subjects with a
BMI≥25 kg/m2. Hence, a potential association
between plasma vaspin levels with body fat distribution could be of
interest in future studies.
Administration of recombinant vaspin to obese mice has been
shown to improve glucose tolerance, insulin sensitivity, and to
alter gene expression of candidate genes for insulin resistance
[9]. In addition, Kloting et al. [31] were able to
demonstrate that central vaspin administration leads to reduced
food intake and has a sustained blood glucose-lowering effects.
Hence, vaspin has become an attractive candidate for drug
development and subsequently there have been substantial research
efforts to identify its importance in insulin resistance in humans.
However, the relationship between circulating vaspin levels and the
parameters of insulin sensitivity and glucose metabolism remains
controversial in human [15, 19]. In this study, we found no
correlation between vaspin and fasting plasma glucose, fasting
insulin and HOMA-IR. Similar results were also obtained in several
recently published studies [11, 12, 19]. Von Loeffelholz
et al. [19] demonstrated that vaspin does not correlate with
insulin resistance measured using both euglycemic-hyperinsulinemic
clamps and HOMA-IR, in a cross-section of 108 non-diabetic
volunteers. Moreover, they found no effect of short-term
lipid-induced insulin resistance due to a 300 min intravenous
lipid challenge on serum vaspin. More recently, Oberbach et
al. [17] demonstrated that short- and long-term exercise
training decreases vaspin serum concentration through increased
oxidative-stress, whereas changes in insulin-sensitivity do not
seem to regulate circulating vaspin. Conversely, several studies
reported a significant correlation between plasma levels of vaspin
and HOMA-IR [10, 13-16, 18, 20]. Handisurya et
al. [14] have shown that following RYGB surgery, changes in
serum vaspin concentrations are significantly associated with the
reduction in plasma levels of insulin and C-peptide, and with the
amelioration of insulin sensitivity. Our data are contradictory to
their data and the reasons for these discrepancies are unclear
[14, 20]. Our subjects underwent restrictive bariatric surgery
while Handisurya et al. performed a malabsorptive surgery
(RYGB). There is evidence that these two types of bariatric surgery
differ to some extent with respect to both efficacy, and the
underlying mechanisms of action in insulin homeostasis [32].
Moreover, we assessed the effect of bariatric surgery on metabolic
profile and vaspin levels in a short-term follow-up (six weeks
after surgery), while they evaluated their subjects after 12
months. In other words, improvement in parameters of
insulin-resistance might require longer periods of restricted
intake following bariatric surgery.
The novel aspect of our study was that for the first time we
specifically assessed the short-term effect of restrictive
bariatric surgery on plasma levels of vaspin. Furthermore, we
attempted to investigate the potential effect of dietary intake on
circulating vaspin that had not been addressed in previous studies
[10-20, 30]. Wang et al. [23] recently showed that a
16-week, high-fat diet could induce metabolic syndrome and
accordingly lower vaspin levels in serum and periepididymal fat in
rats, while pioglitazone and a 4-week calorie-restriction could
increase the production of vaspin. However, they emphasized that
further studies are needed to clarify whether dietary control
accelerates or decelerates the production of vaspin and its
mechanism of regulation in humans. In the present study, we
demonstrated for the first time that, independent of sex and
changes in WC and HOMA-IR, the changes in serum vaspin were
positively associated with a reduction in total daily calorie
intake as well as intakes of fat and protein following bariatric
surgery. Taken together, it may be speculated that decreased levels
of vaspin early after restrictive bariatric surgery seem more
likely to result from decreased dietary intake rather than a weight
loss-induced, insulin sensitivity improvement.
One limitation of our study was the use of the surrogate index,
HOMA-IR, instead of a euglycemic-hyperinsulinemic method, the
standard method used to define insulin resistance. However,
estimates using the HOMA-IR correlates well with those obtained
from the euglycemic-hyperinsulinemic clamp (r=0.83,
P<0.01) and have an acceptable degree of reproducibility
[33].
In conclusion, our findings show that restrictive bariatric
surgery in morbidly obese subjects leads to reduction in plasma
concentrations of vaspin. Furthermore, our study demonstrated that
decreased dietary intake might explain the reduction in vaspin
levels following bariatric surgery, at least in part, whereas
changes in insulin-sensitivity do not seem to be accountable for
the decreased levels of vaspin early after bariatric surgery.
Disclosure: Financial support: This research was
supported by Tehran University of Medical Sciences & Health
services (Tehran, Iran) grants. Conflict of interest: none.
Acknowledgement
AG contributed to designing and performing the study, and
revised the article. NT contributed to data collection. FM analyzed
the data and wrote the article. ZK contributed to performing the
study. MT performed the bariatric surgeries. MH was the
epidemiological consultant and analyzed the data. MJH was the chief
researcher and contributed to idea formation, designing and
managing the research project.
References
1. Hossain P, Kawar B, El Nahas M. Obesity and diabetes
in the developing world – a growing challenge. N Engl
J Med 2007: 356; 213.
2. Mello MM, Studdert DM, Brennan TA.
Obesity – the new frontier of public health law. N
Engl J Med 2006: 354; 2601.
3. Fantuzzi G. Adipose tissue, adipokines, and
inflammation. J Allergy Clin Immunol 2005: 115; 911.
4. Yudkin JS. Adipose tissue, insulin action and vascular
disease: inflammatory signals. Int J Obes Relat Metab Disord
2003: 27 Suppl 3; S25.
5. Ahima RS, Osei SY. Adipokines in obesity. Front
Horm Res 2008: 36; 182.
6. Frayn KN, Karpe F, Fielding BA, et al.
Integrative physiology of human adipose tissue. Int J Obes Relat
Metab Disord 2003: 27; 875.
7. Lago F, Dieguez C, Gomez-Reino J, et al. The
emerging role of adipokines as mediators of inflammation and immune
responses. Cytokine Growth Factor Rev 2007: 18; 313.
8. Wozniak SE, Gee LL, Wachtel MS, et al. Adipose
tissue: the new endocrine organ? A review article. Dig Dis
Sci 2009: 54; 1847.
9. Hida K, Wada J, Eguchi J, et al. Visceral
adipose tissue-derived serine protease inhibitor: a unique
insulin-sensitizing adipocytokine in obesity. Proc Natl Acad Sci
U S A 2005: 102; 10610.
10. Kloting N, Berndt J, Kralisch S, et al. Vaspin
gene expression in human adipose tissue: association with obesity
and type 2 diabetes. Biochem Biophys Res Commun 2006: 339;
430.
11. Chang HM, Lee HJ, Park HS, et al. Effects of
weight reduction on serum vaspin concentrations in obese subjects:
modification by insulin resistance. Obesity (Silver Spring)
2010: 18; 2105.
12. Chang HM, Park HS, Park CY, et al. Association
between serum vaspin concentrations and visceral adipose tissue in
Korean subjects. Metabolism 2010: 59; 1276.
13. Cho JK, Han TK, Kang HS. Combined effects of body
mass index and cardio/respiratory fitness on serum vaspin
concentrations in Korean young men. Eur J Appl Physiol 2010:
108; 347.
14. Handisurya A, Riedl M, Vila G, et al. Serum
vaspin concentrations in relation to insulin sensitivity following
RYGB-induced weight loss. Obes Surg 2010: 20; 198.
15. Korner A, Neef M, Friebe D, et al. Vaspin is
related to gender, puberty and deteriorating insulin sensitivity in
children. Int J Obes (Lond) 2011: 35; 578.
16. Lee MK, Jekal Y, Im JA, et al. Reduced serum
vaspin concentrations in obese children following short-term
intensive lifestyle modification. Clin Chim Acta 2010: 411;
381.
17. Oberbach A, Kirsch K, Lehmann S, et al. Serum
vaspin concentrations are decreased after exercise-induced
oxidative stress. Obes Facts 2010: 3; 328.
18. Suleymanoglu S, Tascilar E, Pirgon O, et al.
Vaspin and its correlation with insulin sensitivity indices in
obese children. Diabetes Res Clin Pract 2009: 84; 325.
19. von Loeffelholz C, Mohlig M, Arafat AM, et al.
Circulating vaspin is unrelated to insulin sensitivity in a cohort
of nondiabetic humans. Eur J Endocrinol 2010: 162; 507.
20. Youn BS, Kloting N, Kratzsch J, et al. Serum
vaspin concentrations in human obesity and type 2 diabetes.
Diabetes 2008: 57; 372.
21. Koiou E, Tziomalos K, Dinas K, et al. The
effect of weight loss and treatment with metformin on serum vaspin
levels in women with polycystic ovary syndrome. Endocr J
2011: 58; 237.
22. Bluher M. Vaspin in obesity and diabetes:
pathophysiological and clinical significance. Endocrine
2011.
23. Wang YM, Wang WP, Wang LP, et al. Calorie
control increased vaspin levels of serum and periepididymal adipose
tissue in diet-induced obese rats in association with serum free
fatty acid and tumor necrosis factor alpha. Chin Med J
(Engl) 2010: 123; 936.
24. Yermilov I, McGory ML, Shekelle PW, et al.
Appropriateness criteria for bariatric surgery: beyond the NIH
guidelines. Obesity (Silver Spring) 2009: 17; 1521.
25. Weiss HG, Nehoda H, Labeck B, et al.
Adjustable gastric and esophagogastric banding: a randomized
clinical trial. Obes Surg 2002: 12; 573.
26. Talebpour M, Amoli BS. Laparoscopic total gastric
vertical plication in morbid obesity. J Laparoendosc Adv Surg
Tech A 2007: 17; 793.
27. Craig CL, Marshall AL, Sjostrom M, et al.
International physical activity questionnaire: 12-country
reliability and validity. Med Sci Sports Exerc 2003: 35;
1381.
28. Matthews DR, Hosker JP, Rudenski AS, et al.
Homeostasis model assessment: insulin resistance and beta-cell
function from fasting plasma glucose and insulin concentrations in
man. Diabetologia 1985: 28; 412.
29. Aust G, Richter O, Rohm S, et al. Vaspin serum
concentrations in patients with carotid stenosis.
Atherosclerosis 2009: 204; 262.
30. Seeger J, Ziegelmeier M, Bachmann A, et al.
Serum levels of the adipokine vaspin in relation to metabolic and
renal parameters. J Clin Endocrinol Metab 2008: 93; 247.
31. Kloting N, Kovacs P, Kern M, et al. Central
vaspin administration acutely reduces food intake and has sustained
blood glucose-lowering effects. Diabetologia 2011: 54;
1819.
32. Butner KL, Nickols-Richardson SM, Clark SF, et
al. A review of weight loss following Roux-en-Y gastric bypass
vs restrictive bariatric surgery: impact on adiponectin and
insulin. Obes Surg 2010: 20; 559.
33. Bonora E, Targher G, Alberiche M, et al.
Homeostasis model assessment closely mirrors the glucose clamp
technique in the assessment of insulin sensitivity: studies in
subjects with various degrees of glucose tolerance and insulin
sensitivity. Diabetes Care 2000: 23; 57.
|